Ironwood Pharmaceuticals, Inc. (IRWD) Revenue by Segment & Business Profile
Collaborative Arrangement Collaboration And License Agreements was 99.5% of Ironwood Pharmaceuticals, Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 571.7M
- P/E TTM
- 4.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What the company does
Ironwood Pharmaceuticals, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 3 business lines: Collaborative Arrangement Collaboration And License Agreements (100%), Collaborative Arrangement Development And Commercialization Agreements (0%), Other (0%). Trailing twelve-month revenue: $389.3 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Specialty pharma
Ironwood Pharmaceuticals, Inc. — questions
- What does Ironwood Pharmaceuticals, Inc. do?
- Ironwood Pharmaceuticals, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 3 business lines: Collaborative Arrangement Collaboration And License Agreements (100%), Collaborative Arrangement Development And Commercialization Agreements (0%), Other (0%). Trailing twelve-month revenue: $389.3 million as of 2026-06-30.
- How does Ironwood Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: Collaborative Arrangement Collaboration And License Agreements 99.5%, Collaborative Arrangement Development And Commercialization Agreements 0.4%, Other 0.1% of revenue.
Every figure on this page comes from Ironwood Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.